Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 4/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2713441 | 0.85 | HDAC6 (0.35) | CA14CTSKHDAC1HDAC2HDAC6 | |
| SCHEMBL3747931 | 0.84 | CA14 (0.40) | CA14CTSKHDAC1HDAC2HDAC6 | |
| SCHEMBL8616170 | 0.81 | NOS2 (0.46) | MEN1GAAKMT2A | |
| SCHEMBL6024664 | 0.79 | CA1 (0.38) | CA14CTSKHDAC1HDAC2HDAC6 | |
| SCHEMBL8310669 | 0.79 | CA14 (0.41) | CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL6525725 | 0.79 | CA14 (0.34) | CA14HDAC1HDAC2HDAC6APLNR | |
| SCHEMBL27942277 | 0.77 | HDAC6 (0.37) | CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL1884648 | 0.77 | CA14 (0.40) | CA14CTSKHDAC1HDAC2HDAC6 | |
| SCHEMBL27662317 | 0.76 | HDAC1 (0.39) | CA14CTSKHDAC1HDAC2HDAC6 | |
| SCHEMBL5287476 | 0.76 | HDAC6 (0.39) | CA14HDAC1HDAC2HDAC6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323418-A1 | SELECTIVE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| EP-2782580-A1 | SELECTIVE KINASE INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2014-10-01 | — | — | EP | disclosed |
| WO-2013078468-A1 | SELECTIVE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323418-A1 | SELECTIVE KINASE INHIBITORS | SYK, BTK, LCK | CA14 4838/4885CTSK 622/4885HDAC1 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.